Neurotechnology company based in Baltimore developing NeuroPASS platform for direct-to-brain therapeutic delivery, bypassing the blood-brain barrier to treat neurological diseases. First fully implantable platform for long-term, programmable drug delivery. Closed $20M Series B.
CraniUS Therapeutics won a second FDA 510(k) clearance in six weeks and a U.S. patent for its NeuroPass-3 cranial drug delivery system.
News from PR Newswire FDA: CraniUS Therapeutics Receives FDA 510(k) Clearance for the CraniUS® Plate, a Patient-Specific Cranial Implant